Femasys (NASDAQ:FEMY) Issues Earnings Results, Misses Estimates By $0.02 EPS

Femasys (NASDAQ:FEMY) released its quarterly earnings results on Friday. The company reported ($1.33) EPS for the quarter, missing the consensus estimate of ($1.31) by ($0.02), Zacks reports. The firm had revenue of $0.33 million for the quarter, compared to analyst estimates of $0.73 million. Femasys had a negative return on equity of 258.08% and a negative net margin of 521.97%.

Femasys Price Performance

NASDAQ FEMY remained flat at $2.29 during mid-day trading on Friday. The company had a trading volume of 116,831 shares, compared to its average volume of 170,721. The stock has a 50-day moving average price of $3.59 and a 200 day moving average price of $7.31. The firm has a market cap of $6.92 million, a P/E ratio of -0.42 and a beta of -2.08. Femasys has a 12-month low of $2.19 and a 12-month high of $22.20. The company has a current ratio of 3.91, a quick ratio of 1.98 and a debt-to-equity ratio of 0.53.

Insiders Place Their Bets

In related news, CEO Kathy Lee-Sepsick acquired 15,625 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The shares were acquired at an average price of $3.20 per share, with a total value of $50,000.00. Following the completion of the purchase, the chief executive officer directly owned 15,625 shares in the company, valued at approximately $50,000. The trade was a ? increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Dov Elefant bought 15,625 shares of the stock in a transaction on Friday, August 7th. The stock was purchased at an average cost of $3.20 per share, with a total value of $50,000.00. Following the completion of the purchase, the chief financial officer directly owned 15,625 shares in the company, valued at $50,000. This trade represents a ? increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders have acquired 38,750 shares of company stock worth $124,000. 7.75% of the stock is owned by company insiders.

Institutional Trading of Femasys

A number of institutional investors and hedge funds have recently made changes to their positions in the company. State Street Corp raised its stake in shares of Femasys by 43.5% in the 4th quarter. State Street Corp now owns 80,869 shares of the company’s stock valued at $47,000 after acquiring an additional 24,500 shares during the period. Kovack Advisors Inc. acquired a new stake in shares of Femasys in the fourth quarter valued at about $27,000. Osaic Holdings Inc. purchased a new stake in shares of Femasys during the 2nd quarter valued at about $45,000. HRT Financial LP purchased a new stake in shares of Femasys during the 4th quarter valued at about $30,000. Finally, Cetera Investment Advisers acquired a new position in Femasys during the 4th quarter worth approximately $36,000. 65.27% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Weiss Ratings raised shares of Femasys from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, July 31st. Maxim Group dropped their target price on Femasys to $10.00 and set a “buy” rating on the stock in a research report on Friday. Finally, Wall Street Zen raised Femasys to a “hold” rating in a research note on Saturday, June 13th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Femasys has a consensus rating of “Moderate Buy” and an average target price of $56.67.

Femasys Company Profile

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.